Table 2. Bcl3 mRNA expression in kidney disease according to transcriptomics databases.
| Condition | Comparator | Species | Fold-change | P-value | Database | Reference |
|---|---|---|---|---|---|---|
| Brain death tubulointerstitium | Cadaveric vs Living donor | Human | 1.45 | 0.057 | Nephromine | 53 |
| Brain death tubulointerstitium | Cadaveric vs Living donor | Human | 1.69 | 0.001 | Nephromine | 54 |
| Hypertension tubulointerstitium | Hypertension vs Living donor | Human | 1.12 | 0.009 | Nephromine | 54 |
| Diabetic nephropathy tubulointerstitium | Diabetes vs minimal change disease | Human | 1.22 | 0.04 | Nephromine | 53 |
| IgA nephropathy tubulointerstitium | Nephrotic vs Sub-nephrotic proteinuria | Human | 1.18 | 0.039 | Nephromine | 55 |
| Glomerulonephritis Tubulointerstitium | Rapidly progressive glomerulonephritis vs Healthy living donor | Human | 1.18 | 0.043 | Nephromine | 54 |
| Thin basement membrane disease Tubulointerstitium | Thin basement membrane disease vs Healthy living donor | Human | 1.21 | 0.009 | Nephromine | 54 |
| Minimal change glomeruli | Minimal change vs Normal control | Human | 1.58 | 0.001 | Nephromine | 56 |
| Membranous glomerulonephritis Glomeruli | Membranous glomerulonephritis vs Healthy living donor | Human | 1.19 | 0.008 | Nephromine | 54 |
| Thin basement membrane disease Glomeruli | Thin basement membrane disease vs Healthy living donor | Human | 1.15 | 0.006 | Nephromine | 54 |
| Diabetic nephropathy Glomeruli | Diabetic nephropathy vs Healthy living donor | Human | 1.2 | 0.027 | Nephromine | 54 |
| Lupus nephritis Glomeruli | Lupus nephritis vs Healthy living donor | Human | 1.09 | 0.042 | Nephromine | 54 |
| Kidney graft | Nephrotoxicity, chronic allograft nephropathy vs Normal kidney | Human | 1.34 | 0.044 | Nephromine | 57 |
| Kidney graft, living donor | Kidney dysfunction vs Normal kidney | Human | 1.46 | 0.0004 | Nephromine | 58 |
| Kidney graft, cadaveric donor | Acute rejection vs No rejection | Human | 1.49 | 0.0004 | Nephromine | 58 |
| Lupus nephritis Glomeruli | MRLLpr vs Control | Mouse | 12.1 | KUPKB | 59 | |
| Lupus nephritis | Proteinuria vs No proteinuria | Mouse | 2.46 | 0.000002 | Nephromine | 60 |
| Aquaporin-11 deficiency effect on the kidney | AQP11 null vs Control | Mouse | 3.15 | 0.001 | GEO Profiles | 61 |
| Nephronophthisis | GLIS2 mutant vs WT | Mouse | 1.58 | 0.002 | GEO Profiles | 62 |
| Dent disease | CLCN5 null vs WT | Mouse | 1.46 | 0.048 | GEO Profiles | 63 |
| Hypertension | Hypertension vs Normotension | Mouse | 1.13 | 0.024 | GEO Profiles | 64 |
| Hypertension | Hypotension vs Normotension | Mouse | 1.31 | 0.014 | GEO Profiles | 64 |
| Methylmalonic acidemia-associated renal disease | MMA mutant vs WT | Mouse | 1.28 | 0.005 | GEO Profiles | 65 |
| Methylmalonic acidemia-associated renal disease | MMA heterozygote vs WT | Mouse | 1.12 | 0.027 | GEO Profiles | 65 |
| Cephaloridine effect on the kidney | Cephaloridine vs Control | Rat | 2.5 | 0.009 | GEO Profiles | 66 |
| Salt-sensitive hypertension | Dahl vs Control | Rat | 2.12 | 0.007 | GEO Profiles | 67 |
| Polycystic kidney disease | Polycystic kidney disease vs Control | Rat | 1.41 | 0.0002 | KUPKB | 68 |
(GEO profiles (http://www.ncbi.nlm.nih.gov/geoprofiles/?term=bcl3+kidney), Kidney & Urinary Pathway Knowledge Base (kupkb at http://www.kupkb.org/) and nephromine (http://www.nephromine.org/)).